Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.35 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3463703 | 1.00 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTSLC6A5 | |
| SCHEMBL30325241 | 0.98 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2MAPTSLC6A5 | |
| SCHEMBL19996021 | 0.98 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2MAPTSLC6A5 | |
| SCHEMBL29227491 | 0.98 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2MAPTSLC6A5 | |
| SCHEMBL17728067 | 0.98 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2MAPTSLC6A5 | |
| SCHEMBL16293718 | 0.98 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2MAPTSLC6A5 | |
| SCHEMBL16295047 | 0.98 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2MAPTSLC6A5 | |
| SCHEMBL16295094 | 0.98 | HCAR2 (0.44) | HCAR2KEAP1NFE2L2MAPTSLC6A5 | |
| SCHEMBL31681514 | 0.87 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL29626440 | 0.87 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111391-B9 | NEW UNSATURATED FATTY AMINO-ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY | FABRE PIERRE DERMO COSMETIQUE (FR) | 2013-05-29 | — | — | EP | claimed |
| EP-2111391-B1 | NEW UNSATURATED FATTY AMINO-ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY | FABRE PIERRE DERMO COSMETIQUE (FR) | 2012-10-31 | — | — | EP | claimed |
| US-20100240754-A1 | UNSATURATED FATTY AMINO ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY | Pierre Fabre Demo-Cosmetique (FR) | 2010-09-23 | — | — | US | claimed |
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2023059581-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20100240754-A1 | UNSATURATED FATTY AMINO ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY | Pierre Fabre Demo-Cosmetique (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | CDK9, AURKB, AURKC | HCAR2 3774/4885KEAP1 1543/4885NFE2L2 3874/4885 |
| US-20100240754-A1 | UNSATURATED FATTY AMINO ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY | FFAR3, FFAR2, BCAT1 | HCAR2 25/4885KEAP1 668/4885NFE2L2 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.